Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Thank you for your post and the link. To be honest, I'm a still a bit confused.

In your post it says:
"Trial Design AML: to start early next year. AML= about 26K new cases a year. Trial has 120 patients, 60 adjuvent (T Cells), 60 Std of Care"

I got that part, that is the 120 patients that are referred to in yesterdays PR as "Group 1".

The PR says: "Group 1 will comprise 120 adjuvant (disease-free) patients, with the primary endpoint of relapse-free survival of patients receiving MultiTAA-specific T cell therapy versus a control group."

But then yesterdays PR goes on to say: "Group 2 will comprise 40 active disease patients in a single arm, with primary endpoints of complete remission and duration of complete remission."

I don't get the "Group 2" patients that have the primary endpoints of complete remission.

That's the patients I was referring to. Can you tell me what those 40 people are about?

Thank You.